NewsRx

Search our medical news database

Age-Related Macular Degeneration

Macugen data presented at Aspen Retinal Detachment Society meeting

Published in Drug Week, April 2nd, 2004

Eyetech Pharmaceuticals, Inc., (EYET) presented additional data from the VEGF (vascular endothelial growth factor) Inhibition Study in Ocular Neovascularization (VISION) at the Aspen Retinal Detachment Society Meeting.

Previously presented data showed that among the patients receiving 0.3 mg of Macugen, 70% lost less than 3 lines of vision on the eye chart, compared with 55% of patients receiving sham injection, a 27% relative difference.

The new data suggest that the overall efficacy is independent of lesion size and patient age. Specifically, statistical interaction tests indicate efficacy is similar in small and large lesions (>4 Disc Areas vs....

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook